# ICU Medical Inc: overview

ICUI · Nasdaq · CIK 883984 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/icui.md) · [Financials](/companies/icui/financials.md) · [Filings](/companies/icui/filings.md) · [Insiders](/companies/icui/insiders.md)

Latest reported revenue: [$551.7m](/filings/0000883984-26-000041.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0000883984-26-000041).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [589](/filings/0000883984-25-000035.md) | [630 d](/filings/0000883984-26-000008.md) | [605](/filings/0000883984-26-000029.md) | [549](/filings/0000883984-26-000041.md) | [537](/filings/0000883984-25-000035.md) | [541 d](/filings/0000883984-26-000008.md) | [530](/filings/0000883984-26-000029.md) | [552](/filings/0000883984-26-000041.md) |
| Gross margin | % | [34.8%](/filings/0000883984-25-000035.md) | [36.1% d](/filings/0000883984-26-000008.md) | [34.7%](/filings/0000883984-26-000029.md) | [37.9%](/filings/0000883984-26-000041.md) | [37.4%](/filings/0000883984-25-000035.md) | [37.5% d](/filings/0000883984-26-000008.md) | [38.9%](/filings/0000883984-26-000029.md) | [42.6%](/filings/0000883984-26-000041.md) |
| Operating margin | % | [1.4%](/filings/0000883984-25-000035.md) | [6.0% d](/filings/0000883984-26-000008.md) | [2.1%](/filings/0000883984-26-000029.md) | [1.9%](/filings/0000883984-26-000041.md) | [2.6%](/filings/0000883984-25-000035.md) | [1.0% d](/filings/0000883984-26-000008.md) | [2.6%](/filings/0000883984-26-000029.md) | [7.1%](/filings/0000883984-26-000041.md) |
| Net margin | % | [(5.6%)](/filings/0000883984-25-000035.md) | [(3.8%) d](/filings/0000883984-26-000008.md) | [(2.6%)](/filings/0000883984-26-000041.md) | [6.4%](/filings/0000883984-26-000041.md) | [(0.6%)](/filings/0000883984-25-000035.md) | [(2.9%) d](/filings/0000883984-26-000008.md) | [5.7%](/filings/0000883984-26-000041.md) | [3.5%](/filings/0000883984-26-000041.md) |
| Diluted EPS | $ per share | [(1.35)](/filings/0000883984-25-000035.md) | not reported | [(0.63)](/filings/0000883984-26-000029.md) | [1.43](/filings/0000883984-26-000041.md) | [(0.14)](/filings/0000883984-25-000035.md) | not reported | [1.20](/filings/0000883984-26-000029.md) | [0.76](/filings/0000883984-26-000041.md) |
| Free cash flow | $m | [16.2 d](/filings/0000883984-25-000035.md) | [16.1 d](/filings/0000883984-26-000008.md) | [36.7](/filings/0000883984-26-000029.md) | [(8.5) d](/filings/0000883984-26-000041.md) | [27.6 d](/filings/0000883984-25-000035.md) | [36.0 d](/filings/0000883984-26-000008.md) | [27.6](/filings/0000883984-26-000029.md) | [61.6 d](/filings/0000883984-26-000041.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,316](/filings/0000883984-24-000005.md) | [2,280](/filings/0000883984-25-000007.md) | [2,259](/filings/0000883984-26-000008.md) | [2,382](/filings/0000883984-26-000008.md) | [2,231](/filings/0000883984-26-000008.md) |
| Gross margin | % | [37.3%](/filings/0000883984-24-000005.md) | [30.6%](/filings/0000883984-25-000007.md) | [32.8%](/filings/0000883984-26-000008.md) | [34.6%](/filings/0000883984-26-000008.md) | [36.8%](/filings/0000883984-26-000008.md) |
| Operating margin | % | [9.4%](/filings/0000883984-24-000005.md) | [(1.9%)](/filings/0000883984-25-000007.md) | [1.0%](/filings/0000883984-26-000008.md) | [1.8%](/filings/0000883984-26-000008.md) | [1.9%](/filings/0000883984-26-000008.md) |
| Net margin | % | [7.8%](/filings/0000883984-24-000005.md) | [(3.3%)](/filings/0000883984-25-000007.md) | [(1.3%)](/filings/0000883984-26-000008.md) | [(4.9%)](/filings/0000883984-26-000008.md) | [0.0%](/filings/0000883984-26-000008.md) |
| Diluted EPS | $ per share | [4.74](/filings/0000883984-24-000005.md) | [(3.11)](/filings/0000883984-25-000007.md) | [(1.23)](/filings/0000883984-26-000008.md) | [(4.83)](/filings/0000883984-26-000008.md) | [0.03](/filings/0000883984-26-000008.md) |
| Free cash flow | $m | [199](/filings/0000883984-24-000005.md) | [(152)](/filings/0000883984-25-000007.md) | [82.3](/filings/0000883984-26-000008.md) | [125](/filings/0000883984-26-000008.md) | [91.8](/filings/0000883984-26-000008.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/icui/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $550.2m | 3,753,409 |  | Added +145,087 |
| [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $407.8m | 2,781,620 |  | Not compared |
| [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $345.6m | 2,676,012 |  | Not compared |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $215.6m | 1,470,583 |  | Added +32,907 |
| [FULLER & THALER ASSET MANAGEMENT, INC.](/funds/1082327.md) | 2026-06-30 | $190.3m | 1,298,127 |  | Added +77,588 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $164.7m | 1,123,237 |  | Added +11,362 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $154.4m | 1,053,476 |  | Added +69,674 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $150.2m | 1,024,369 |  | Added +56,316 |
| [SCHRODER INVESTMENT MANAGEMENT GROUP](/funds/1086619.md) | 2026-06-30 | $109.3m | 739,138 |  | Added +37,858 |
| [AMERIPRISE FINANCIAL INC](/funds/820027.md) | 2026-06-30 | $101.1m | 689,573 |  | Added +83,845 |

## Recent filings

[All 1,450 filings](/companies/icui/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-06 | 16:34 ET | [10-Q](/filings/0000883984-26-000041.md) | Quarterly report, period 2026-06-30 | 0000883984-26-000041 |
| 2026-08-06 | 16:11 ET | [8-K](/filings/0000883984-26-000040.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000883984-26-000040 |
| 2026-05-18 | 12:35 ET | [8-K](/filings/0000883984-26-000031.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000883984-26-000031 |
| 2026-05-07 | 16:20 ET | [10-Q](/filings/0000883984-26-000029.md) | Quarterly report, period 2026-03-31 | 0000883984-26-000029 |
| 2026-05-07 | 16:11 ET | [8-K](/filings/0000883984-26-000028.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000883984-26-000028 |
| 2026-04-02 | 16:07 ET | [DEF 14A](/filings/0000883984-26-000019.md) | Proxy statement, period 2026-05-13 | 0000883984-26-000019 |
| 2026-02-20 | 16:27 ET | [8-K](/filings/0000883984-26-000010.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000883984-26-000010 |
| 2026-02-19 | 16:40 ET | [10-K](/filings/0000883984-26-000008.md) | Annual report, period 2025-12-31 | 0000883984-26-000008 |
| 2026-02-19 | 16:08 ET | [8-K](/filings/0000883984-26-000007.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000883984-26-000007 |
| 2025-11-06 | 16:39 ET | [10-Q](/filings/0000883984-25-000035.md) | Quarterly report, period 2025-09-30 | 0000883984-25-000035 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0000883984-26-000008.md), filed Feb 19, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/3e4c682a-4a66-4829-bb8c-a83e82b3793f)

## About the filer

- CIK: 883984
- Tickers: ICUI
- Exchange: Nasdaq
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:27 ET. No prices; not investment advice.